GSK's Experimental Asthma Drug Shows Promise in Late-Stage Trials, Potential £3 Billion Sales

May 21, 2024, 07:01 AM

An experimental drug from GlaxoSmithKline (GSK) has shown promising results in reducing severe asthma attacks in late-stage trials. The British pharmaceutical company announced on Tuesday that the drug met its primary goal of reducing asthma attacks over a 52-week period in a key trial. The success of these trials paves the way for a treatment that GSK believes could exceed £3 billion in sales, potentially making it a blockbuster product.